Immucell (ICCC) Change in Receivables (2010 - 2025)
Immucell's (ICCC) quarterly Change in Receivables came in at $864243.0 in Q4 2025, down 40.94% YoY from $1.5 million in Q4 2024, and up 391.21% on a QoQ basis from $175943.0 in Q3 2025.
Immucell (ICCC) Change in Receivables (2010 - 2025) Analysis & Trends
Immucell (ICCC) has 16 years of Change in Receivables data on file, last reported at $864243.0 in Q4 2025.
- Quarterly Change in Receivables fell 40.94% year-over-year to $864243.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$352124.0 (down 122.21% YoY) and the FY2025 annual result came in at -$352124.0, down 122.21% from the prior year.
- Change in Receivables improved to $864243.0 in Q4 2025, from $175943.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $1.5 million in Q4 2024 to a low of -$1.2 million in Q2 2022.
- A 5-year average of $81110.4 and a median of $280050.0 in 2021 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables plunged 264.1% — and 2023, when it soared 896.63%.
- Tracing ICCC's Change in Receivables over 5 years: stood at $271974.0 in 2021, then tumbled by 79.13% to $56770.0 in 2022, then jumped by 465.08% to $320798.0 in 2023, then jumped by 356.12% to $1.5 million in 2024, then plunged by 40.94% to $864243.0 in 2025.
- The last three Change in Receivables figures came in at $864243.0 (Q4 2025), $175943.0 (Q3 2025), and -$967602.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 864,243.00 |
| Dec 31, 2025 | 864,243.00 |
| Sep 30, 2025 | 175,943.00 |
| Sep 30, 2025 | 175,943.00 |
| Jun 30, 2025 | -967,602.00 |
| Jun 30, 2025 | -967,602.00 |
| Mar 31, 2025 | -424,708.00 |
| Mar 31, 2025 | -424,708.00 |
| Dec 31, 2024 | 1.46 Mn |
| Dec 31, 2024 | 1.46 Mn |
| Sep 30, 2024 | 357,463.00 |
| Sep 30, 2024 | 357,463.00 |
| Jun 30, 2024 | -672,082.00 |
| Jun 30, 2024 | -672,082.00 |
| Mar 31, 2024 | 437,149.00 |
| Mar 31, 2024 | 437,149.00 |
| Dec 31, 2023 | 320,798.00 |
| Dec 31, 2023 | 320,798.00 |
| Sep 30, 2023 | 365,737.00 |
| Sep 30, 2023 | 365,737.00 |